BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22635233)

  • 1. Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite antiphospholipid syndrome.
    Banzato A; Frasson R; Acquasaliente L; Bison E; Bracco A; Denas G; Cuffaro S; Hoxha A; Ruffatti A; Iliceto S; De Filippis V; Pengo V
    Lupus; 2012 Jun; 21(7):784-6. PubMed ID: 22635233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The avidity of anti-beta2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: a collaborative study in the frame of the European forum on antiphospholipid antibodies.
    Cucnik S; Kveder T; Ulcova-Gallova Z; Swadzba J; Musial J; Valesini G; Avcin T; Rozman B; Bozic B
    Lupus; 2011 Oct; 20(11):1166-71. PubMed ID: 21712304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review.
    Bruce IN; Clark-Soloninka CA; Spitzer KA; Gladman DD; Urowitz MB; Laskin CA
    J Rheumatol; 2000 Dec; 27(12):2833-7. PubMed ID: 11128672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome.
    Cucnik S; Kveder T; Krizaj I; Rozman B; Bozic B
    Ann Rheum Dis; 2004 Nov; 63(11):1478-82. PubMed ID: 15479898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome.
    Kajiwara T; Yasuda T; Matsuura E
    J Autoimmun; 2007; 29(2-3):164-73. PubMed ID: 17826950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome.
    Hanly JG; Smith SA
    J Rheumatol; 2000 Sep; 27(9):2152-9. PubMed ID: 10990227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of complement component C1q to anti-beta2 glycoprotein I antibodies from patients with antiphospholipid syndrome.
    Odorczuk M; Keil LB; DeBari VA
    Inflamm Res; 1999 Oct; 48(10):524-6. PubMed ID: 10563468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant.
    Yasuda S; Atsumi T; Matsuura E; Kaihara K; Yamamoto D; Ichikawa K; Koike T
    Arthritis Rheum; 2005 Jan; 52(1):212-8. PubMed ID: 15641049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation.
    Rahgozar S; Yang Q; Giannakopoulos B; Yan X; Miyakis S; Krilis SA
    Arthritis Rheum; 2007 Feb; 56(2):605-13. PubMed ID: 17265495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
    Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A
    Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome.
    Fanopoulos D; Teodorescu MR; Varga J; Teodorescu M
    J Rheumatol; 1998 Apr; 25(4):675-80. PubMed ID: 9558168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies to oxLig-1/beta2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome.
    Lopez D; Garcia-Valladares I; Palafox-Sanchez CA; De La Torre IG; Kobayashi K; Matsuura E; Lopez LR
    Am J Clin Pathol; 2004 Mar; 121(3):426-36. PubMed ID: 15023048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome.
    Robbins DL; Leung S; Miller-Blair DJ; Ziboh V
    J Rheumatol; 1998 Jan; 25(1):51-6. PubMed ID: 9458202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity.
    Pengo V; Biasiolo A; Bison E; Chantarangkul V; Tripodi A;
    Thromb Res; 2007; 120(1):127-33. PubMed ID: 17020782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of low-molecular-weight heparin on adhesion and vesiculation of phospholipid membranes: a possible mechanism for the treatment of hypercoagulability in antiphospholipid syndrome.
    Frank M; Sodin-Semrl S; Rozman B; Potocnik M; Kralj-Iglic V
    Ann N Y Acad Sci; 2009 Sep; 1173():874-86. PubMed ID: 19758240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous recognition of beta 2-glycoprotein I by antibodies from antiphospholipid syndrome patients.
    Guerin J; Sim R; Yu BB; Ferluga J; Feighery C; Jackson J
    Thromb Haemost; 2000 Sep; 84(3):374-80. PubMed ID: 11019958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model.
    Blank M; Anafi L; Zandman-Goddard G; Krause I; Goldman S; Shalev E; Cervera R; Font J; Fridkin M; Thiesen HJ; Shoenfeld Y
    Int Immunol; 2007 Jul; 19(7):857-65. PubMed ID: 17576752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to Domain I of β(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS).
    Banzato A; Pozzi N; Frasson R; De Filippis V; Ruffatti A; Bison E; Padayattil SJ; Denas G; Pengo V
    Thromb Res; 2011 Dec; 128(6):583-6. PubMed ID: 21620443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.